Britain’s largest pharmaceutical companies have raised urgent concerns over what they describe as an “excessive” NHS sales rebate, warning it is harming investment in an economically crucial sector. Industry leaders
Britain’s largest pharmaceutical companies have raised urgent concerns over what they describe as an “excessive” NHS sales rebate, warning it is harming investment in an economically crucial sector. Industry leaders






